title: A randomized, comparative open-label study on the efficacy of latanoprost and timolol in steroid induced ocular hypertension after photorefractive keratectomy.
abstract: OBJECTIVE
  To evaluate the effect of 0.005% latanoprost and 0.50% timolol for the treatment of steroid-induced ocular hypertension (SIOH) after excimer laser photorefractive keratectomy (PRK).
  
  
  METHODS
  In this comparative, open-label study we enrolled 29 patients who received steroid therapy after PRK and developed intraocular pressure (IOP) elevation within 30 days of treatment. Fifteen were randomized to 0.005% latanoprost (group A) and 14 to 0.50% timolol (group B). IOP measurements were scheduled at 1, 3, 7, 15, 30, 60, 90 and 120 days of therapy. RESULTS; We did not find any real differences between latanoprost and timolol except at the 7-day and 15-day timepoints, when latanoprost reduced IOP significantly more than timolol (p=0.033, 0.035, respectively). After 7 days of therapy two of the 14 timolol-treated patients had high IOP (24 and 26 mmHg) but these promptly returned to normal when latanoprost was added. No significant differences were observed in the ocular side effects considered.
  
  
  CONCLUSIONS
  0.005% latanoprost is as safe and effective as 0.50% timolol in the treatment of SIOH after PRK. Both drugs provide a significant and stable IOP reduction in the majority of patients after short-term treatment. These findings are encouraging for the use of latanoprost in the management of SIOH after PRK, although further trials are necessary to consider it as a primary treatment.
authors.affiliation: Department of Ophthalmology, Otorhinolaryngology, University of Bari, Italy. m.vetrugno@oftalmo.uniba.it
authors.forename: M
authors.initials: M
authors.lastname: Vetrugno
authors.forename: A
authors.initials: A
authors.lastname: Maino
authors.forename: G M
authors.initials: GM
authors.lastname: Quaranta
authors.forename: L
authors.initials: L
authors.lastname: Cardia
mesh_terms: D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D005260:Female; D005469:Fluorometholone / Q000009:adverse effects; D005938:Glucocorticoids; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D054018:Lasers, Excimer; D000077338:Latanoprost; D008297:Male; D009216:Myopia / Q000601:surgery; D009798:Ocular Hypertension / Q000139:chemically induced / Q000188:drug therapy*; D009883:Ophthalmic Solutions; D018903:Photorefractive Keratectomy; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*; D012449:Safety; D013999:Timolol / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D013999:Timolol; D005469:Fluorometholone